Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Basit Öğe Kaydı
dc.authoridGlintborg, Bente/0000-0002-8931-8482
dc.authoridChristiansen, Sara Nysom/0000-0002-5063-9932
dc.authoridMichelsen, Brigitte/0000-0003-0103-2840
dc.authoridSantos, Maria Jose/0000-0002-7946-1365
dc.authoridMacfarlane, Gary/0000-0003-2322-3314
dc.authoridCiurea, Adrian/0000-0002-7870-7132
dc.authoridLoft, Anne Gitte/0000-0001-6374-841X
dc.contributor.authorChristiansen, Sara Nysom
dc.contributor.authorRasmussen, Simon Horskjaer
dc.contributor.authorOstergaard, Mikkel
dc.contributor.authorPons, Marion
dc.contributor.authorMichelsen, Brigitte
dc.contributor.authorPavelka, Karel
dc.contributor.authorCodreanu, Catalin
dc.date.accessioned2025-03-20T09:50:47Z
dc.date.available2025-03-20T09:50:47Z
dc.date.issued2024
dc.departmentİzmir Bakırçay Üniversitesi
dc.description.abstractObjectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non- radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe. Methods Prospectively collected data on secukinumab- treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient- reported outcomes (PROs; Numeric Rating Scale (0-10), for example, pain <= 2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <= 2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID) <1.3 after 6/12/24 months of secukinumab treatment were calculated.Remission and drug retention rates in r- axSpA versus nr- axSpA patients were compared by logistic and Cox regression models (unadjusted/adjusted for age+sex/adjusted for multiple confounders).Results Overall, 1161 secukinumab- treated patients were included (r- axSpA/nr- axSpA: 922/239). At baseline, r- axSpA patients had longer disease duration and higher C reactive protein, were more often male and HLA- B27 positive and had received fewer prior biological or targeted synthetic disease- modifying antirheumatic drugs compared with nr- axSpA patients, whereas PROs were largely similar.During follow- up, crude PRO remission rates were significantly higher in r- axSpA compared with nr- axSpA patients (6 months: pain <= 2: 40%/28%, OR=1.7; BASDAI <= 2: 37%/25%, OR=1.8), as were drug retention rates (24 months: 66%/58%, HR 0.73 (ref: r- axSpA)). Proportions of patients achieving ASDAS ID were low for both groups, particularly nr- axSpA (6 months: 11%/8%) However, when adjusting for age+sex, these differences diminished, and after adjusting for multiple confounders, no significant between- group differences remained for either remission or drug retention rates.Conclusion Crude remission/drug retention rates in European secukinumab- treated patients were higher n r- axSpA compared with nr- axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups, suggesting that observed differences were related to factors other than radiographic status.
dc.description.sponsorshipNovartis
dc.description.sponsorshipThis work was supported by Novartis. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit.
dc.identifier.doi10.1136/rmdopen-2024-004166
dc.identifier.issn2056-5933
dc.identifier.issue3
dc.identifier.pmid39053949
dc.identifier.scopus2-s2.0-85199661747
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1136/rmdopen-2024-004166
dc.identifier.urihttps://hdl.handle.net/20.500.14034/2311
dc.identifier.volume10
dc.identifier.wosWOS:001307813900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmj Publishing Group
dc.relation.ispartofRmd Open
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250319
dc.subjectSpondylitis
dc.subjectAnkylosing
dc.subjectEpidemiology
dc.subjectPatient Reported Outcome Measures
dc.subjectPain
dc.subjectTherapeutics
dc.titleEffectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu